Chronic severe uveitis: Classification, search for etiology and therapeutic approach;Uvéites chroniques sévères: Classification, démarche diagnostique et principes thérapeutiques

Revue de Medecine Interne

Volumn 24, Issue 12, 2003, Pages 794-802

  Bodaghi, B ^a   Wechsler, B ^a   Du Boutin, L T H ^a   Cassoux, N ^a   LeHoang, P ^a   Piette, J C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Beh et's disease; Blindness; Epidemiology; Etiology; Immunosuppresive drugs; Ocular infections; Tuberculosis; Uveitis; Whipple's disease

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; METHYLPREDNISOLONE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; BLINDNESS; CHRONIC SEVERE UVEITIS; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EYE DISEASE; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; IMMUNE MEDIATED INJURY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; OPTICAL COHERENCE TOMOGRAPHY; POLYMERASE CHAIN REACTION; SYSTEMIC DISEASE; UVEITIS; VIRUS EXAMINATION; VISION;

EID: 0347625739     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(03)00140-1     Document Type: Short Survey

References (68)

1. Banares A, Jover JA, Fernandez-Gutierrez B, Benitez del Castillo JM, Garcia J, Vargas E, et al. Patterns of uveitis as a guide in making rheumatologic and immunologic diagnoses. Arthritis Rheum 1997;40:358-70.
2. Bloch Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987;103:204-5.
3. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European spondylarthropathy study group preliminary criteria for the classification of spondylarthropathy [see comments]. Arthritis Rheum 1991;34:1218-27.
4. Brophy S, Pavy S, Lewis P, Taylor G, Bradbury L, Robertson D, et al. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J Rheumatol 2001;28:2667-73.
5. Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol 2002;14:337-41.
6. Pato E, Banares A, Jover JA, Fernandez-Gutierrez B, Godoy F. Morado C, et al. Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis. J Rheumatol 2000;27:2198-202.
7. Rosenbaum JT. Characterization of uveitis associated with spondyloarthritis. J Rheumatol 1989;16:792-6.
8. Rosenbaum JT. Acute anterior uveitis and spondyloarthropathies. Rheum Dis Clin North Am 1992;18:143-51.
9. Smith JR. HLA B27-associated uveitis. Ophthalmol Clin North Am 2002;15:297-307.
10. Tay-Kearney ML, Schwam BL, Lowder C, Dunn JP, Meisler DM, Vitale S, et al. Clinical features and associated systemic diseases of HLA B27 uveitis. Am J Ophthalmol 1996;121:47-56.
11. Paiva ES, Macaluso DC, Edwards A, Rosenbaum JT. Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis 2000;59:67-70.
12. De Boer JH, Verhagen C, Bruinenberg M, Rothova A, de Jong PT, Baarsma GS, et al. Serologic and polymerase chain reaction analysis of intraocular fluids in the diagnosis of infectious uveitis. Am J Ophthalmol 1996;121:650-8.
13. Criteria for diagnosis of Behcet's disease. International Study Group for Behçet's Disease. Lancet 1990;335:1078-80.
14. Read RW, Vogt-Koyanagi-Harada disease. Ophthalmol Clin North Am 2002;15:333-41.
15. Yamaki K, Gocho K, Sakuragi S. Pathogenesis of Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin 2002;42:13-23.
16. Fardeau C, Romand S, Rao NA, Cassoux N, Bettembourg O, Thulliez P, et al. Diagnosis of toxoplasmic retinochoroiditis with atypical clinical features. Am J Ophthalmol 2002;134:196-203.
17. Barile GR, Flynn TE. Syphilis exposure in patients with uveitis. Ophthalmology 1997;104:1605-9.
18. Bodaghi B, LeHoang P. Ocular tuberculosis. Curr Opin Ophthalmol 2000:443-8.
19. Dutly F, Altwegg M. Whipple's disease and Tropheryma whippelii. Clin Microbiol Rev 2001;14:561-83.
20. Bodaghi B, Dauga C, Cassoux N, Wechsler B, Merle-Beral H, Poveda JD, et al. Whipple's syndrome (uveitis, B27-negative spondylarthropathy, meningitis, and lymphadenopathy) associated with Arthrobacter sp. infection. Ophthalmology 1998;105:1891-6.
21. Ramzan NN, Loftus Jr E, Burgart LJ, Rooney M, Batts KP, Wiesner RH, et al. Diagnosis and monitoring of Whipple disease by polymerase chain reaction. Ann Intern Med 1997;126:520-7.
22. Rickman LS, Freeman WR, Green WR, Feldman ST, Sullivan J, Russack V, et al. Brief report: uveitis caused by Tropheryma whippelii (Whipple's bucillus). N Engl J Med 1995;332:363-6.
23. Raoult D, Birg ML, La Scola B, Fournier PE, Enea M, Lepidi H, et al. Cultivation of the bacillus of Whipple's disease. N Engl J Med 2000;342:620-5.
24. Bodaghi B, Cassoux N, Wechsler B, Hannouche D, Fardeau C, Papo T, et al. Chronic severe uveitis. Etiology and visual outcome in 927 patients from a single center. Medicine 2001;80:263-70.
25. The World Health Report, Data on visual impairement. Prevention of blindness (PBL) http:/www.who.int/pbd/pbl/data.htm#definitions. Accessed March 2001.
26. Thylefors B, Négrel A, Pararajasegaram R, Dadzie K. Global data on blindness. Bull WHO 1995;73:115-21.
27. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol 1990;14:303-8.
28. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996;80:844-8.
29. Thompson JR, Du L, Rosenthal AR. Recent trends in the registration of blindness and partial sight in Leicestershire. Br J Ophthalmol 1989;73:95-9.
30. Darrell R, Wagener H, Kurland L. Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol 1962;68:502-14.
31. ten Doesschate J. Causes of blindness in The Netherlands. Doc Ophthalmol 1982;52:279-85.
32. Saari KM, Paivonsalo-Hietanen T, Vaahtoranta-Lehtonen H, Tuominen J, Sillanpaa M. Epidemiology of endogenous uveitis in south-western Finland. Acta Ophthalmol Scand 1995;73:345-9.
33. Vadot E, Barth E, Billet P. Epidemiology of uveitis: preliminary results of a study in the Savoy. Journal 1984:1-16.
34. Guyton J, Woods A. Etiology of uveitis: a clinical study of 562 cases. Arch Ophthalmol 1941;26:983-1018.
35. Haut J. Classification etiologique de 850 uveites. Arch Ophtalmol Rev Gen Ophtalmol 1966;26:691-4.
36. Haut J, Roman S, Morin Y, Monin C, Morel C. Enquête étiologique dans 110 cas d'uvéites. Intérêt de la ponction de humeur aqueuse et du vitrée. J Fr Ophtalmol 1995;18:292-304.
37. McCannel CA, Holland GN, Helm CJ, Cornell PJ, Winston JV, Rimmer TG. Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. Am J Ophthalmol 1996;121:35-46.
38. Rodriguez A, Calonge M, Pedroza-Seres M, Akova YA, Messmer EM, D'Amico DJ, et al. Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol 1996;114:593-9.
39. Smit RL, Baarsma GS, de Vries J. Classification of 750 consecutive uveitis patients in the Rotterdam Eye Hospital. Int Ophthalmol 1993;17:71-6.
40. Tran VT, Auer C, Guex-Crosier Y, Pittet N, Herbort CP. Epidemiological characteristics of uveitis in Switzerland. Int Ophthalmol 1994;18:293-8.
41. Weiner A, BenEzra D. Clinical patterns and associated conditions in chronic uveitis. Am J Ophthalmol 1991;112:151-8.
42. Bodaghi B, LeHoang P. Testing ocular fluids in uveitis. Ophthalmol Clin North Am 2002;15:271-9.
43. LeHoang P, Cassoux N, George F, Kullmann N, Kazatchkine MD. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul Immunol Inflamm 2000;8:49-57.
44. Isnard Bagnis C, Tezenas Du Montcel S, Beaufils H, Jouanneau C, Jaudon MC, Maksud P, et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol 2002;13:2962-8.
45. Deane JS, Rosenthal AR. Course and complications of intermediate uveitis. Acta Ophthalmol Scand 1997;75:82-4.
46. Dinning WJ. Intermediate uveitis: history, terminology, definition pars planitis: systemic disease associations. Dev Ophthalmol 1992;23:3-8.
47. Lai WW, Pulido JS. Intermediate uveitis. Ophthalmol Clin North Am 2002;15:309-17.
48. Antcliff RJ, Stanford MR, Chauhan DS, Graham EM, Spalton DJ, Shilling JS, et al. Comparison between optical coherence tomography and fundus fluorescein angiography for the detection of cystoid macular edema in patients with uveitis. Ophthalmology 2000;107:593-9.
49. Bozzoni-Pantaleoni F, Gharbiya M, Pirraglia MP, Accorinti M, Pivetti-Pezzi P. Indocyanine green angiographic findings in Behçet disease. Retina 2001;21:230-6.
50. Herbort CP, Bodaghi B, Lehoang P. Indocyanine green angiography in ocular inflammatory diseases: principles, schematic interpretation, semiology and clinical value. J Fr Ophtalmol 2001;24:423-47.
51. Howe L, Stanford M, Graham E, Marshall J. Indocyanine green angiography in inflammatory eye disease. Eye 1998;12:761-7.
52. Kohno T, Miki T, Shiraki K, Kano K, Matsushita M, Hayashi K, et al. Subtraction ICG angiography in Harada's disease. Br J Ophthalmol 1999;83:822-33.
53. Rothova A, Buitenhuis HJ, Meenken C, Brinkman CJ, Linssen A, Alberts C, et al. Uveitis and systemic disease. Br J Ophthalmol 1992;76:137-41.
54. Biswas J, Therese L, Madhavan HN. Use of polymerase chain reaction in detection of Mycobacterium tuberculosis complex DNA from vitreous sample of Eales' disease. Br J Ophthalmol 1999;83:994.
55. Madhavan H, Therese K, Gunisha P. Polymerase chain reaction for detection of Mycobacterium tuberculosis in epiretinal membrane in Eales' disease. Invest Ophthalmol Vis Sci 2000.
56. Goker B, Goker H. Current therapy for Behçet's disease. Am J Ther 2002;9:465-70.
57. Stuebiger N, Koetter I, Zierhut M. Complete regression of retinal neovascularization after therapy with interferon alfa in Behçet's disease. Br J Ophthalmol 2000;84:1437-8.
58. Wechsler B, Bodaghi B, Huong DL, Fardeau C, Amoura Z, Cassoux N, et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm 2000;8:293-301.
59. Estrach C, Mpofu S, Moots RJ. Behçet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford) 2002;41:1213-4.
60. Rosenbaum JT, Smith JR. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol 2002;20:S143-5.
61. Sfikakis PP. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002;61(Suppl 2):51-3.
62. Tutuncu Z, Morgan Jr GJ, Kavanaugh A. Anti-TNF therapy for other inflammatory conditions. Clin Exp Rheumatol 2002;20:S146-51.
63. Lim WS, Powell RJ, Johnston ID. Tuberculosis and treatment with infliximab. N Engl J Med 2002;346:623-6.
64. Mikuls TR, Moreland LW. Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. Drug Saf 2003;26:23-32.
65. Tanner V, Kanski JJ, Frith PA. Posterior sub-Tenon's triamcinolone injections in the treatment of uveitis. Eye 1998;12:679-85.
66. Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol 2001;119:1380-3.
67. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001;108:765-72.
68. Jaffe GJ, Ben-Nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000;107:2024-33.